Bellaseno accelerated development of its absorbable breast scaffold after a faster-than-expected pivotal trial trajectory in Australia and a new licensing deal with Johnson & Johnson’s Mentor Worldwide. The company said the updated arrangements position the technology for global commercialization. The pivot follows renewed focus on scaffold materials that can support breast reconstruction while aiming to reduce complications associated with other approaches. Bellaseno’s development plan includes moving through late-stage requirements after the trial’s recruitment updates. The combination of clinical speed and commercial readiness signals a near-term opportunity for additional regulatory engagements and potential partnering interest.